IPH
INNATE PHARMA
Stock Euronext / Paris – Stock Market Prices, News & Analysis
Innate Pharma is a biotechnology company focused on immunotherapy and antibody research, primarily in the treatment of cancer.
INNATE PHARMA
IPH
Innate Pharma is a biotechnology company focused on immunotherapy and antibody research, primarily in the treatment of cancer.
Price history of INNATE PHARMA
Price history of INNATE PHARMA
Performance & Momentum
Innate Pharma cleared for US phase 3 clinical trial
Innate Pharma has received FDA approval to initiate the phase 3 clinical trial of lacutamab, its potential treatment for cutaneous T-cell lymphoma (CTCL). This approval follows shortly after the publication of the company’s Q3 2025 financial results and its presentation at the Jefferies Global Healthcare conference. Additionally, the stock shows a promising technical pattern indicating a possible trend reversal. These developments could boost investor confidence in the short to medium term.
Strategic Analysis
INNATE PHARMA • 2026
Innate Pharma specializes in the development of innovative immunotherapies focused on antibodies for cancer treatment, leveraging its expertise in biotechnology. Its niche relies on targeted technologies in a high-value but highly competitive sector.
- Innovative positioning in immuno-oncology with a portfolio of promising candidates
- Recognized expertise in therapeutic antibodies
- Presence in a rapidly growing market driven by increasing demand for targeted oncology treatments
- Long and disappointing stock performance, reflecting difficulties in transforming projects into commercial successes
- Lack of recent catalysts or major announcements driving the stock price
The technical momentum is weak and shows a persistent downward trend in the medium to long term, signaling investor skepticism. The absence of recent positive news reinforces caution, necessitating close monitoring of clinical advancements to consider a recovery.
Similar stocks to INNATE PHARMA
Recent News
INNATE PHARMA
Innate Pharma Gets FDA Nod for Phase 3 Trial
5 months agoInnate Pharma has received FDA approval to initiate a Phase 3 clinical trial for lacutamab, targeting cutaneous T-cell lymphomas (CTCL). This key regulatory milestone paves the way to validate the efficacy of this promising treatment for certain skin cancers. Additionally, the formation of a hammer chart pattern indicates strong technical support, bolstered by an upward trend in profit forecasts, which could signal a potential rebound in the stock price.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
